Kadmon Holdings, Inc.: Lead candidate is KD025, a ROCK2 inhibitor in in a pivotal clinical trial for chronic graft-versus-host disease (cGVHD); study outcome to be reported by YE 2019. A Ph2 trial of KD025 in systemic sclerosis is ongoing. Also developing KD033, an anti-PD-L1/IL-15 fusion protein; expected to enter the clinic in Q4 2019.
Based in...
Clinical Stage
Phase l or ll
Disease Space
Autoimmune, Fibrosis, Oncology
Biotechnology, Pharmaceuticals
Public, USA
Market Cap
100MM - 500MM
450 East 29th Street
New York, NY 10016
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Hamptons CEO Roundtable 2019

Bridgehampton, August 15, 2019

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.